Physician profile
Patrick K Chau
NPI 1992766299
$9,527.32
in general payments reported to CMS, 2019-2025
30 companies · $2,639 in 2025
The $2,639 reported for 2025 was more than what 95% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $134 · 2021: $1,441 · 2022: $1,192 · 2023: $1,665 · 2024: $2,455 · 2025: $2,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,596 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,596.25 |
| Education | $162.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,486.37 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,070.67 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $1,047.67 | 2020-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $887.85 | 2020-2025 | Caplyta |
| Lundbeck LLC | $747.51 | 2020-2025 | Rexulti |
| Alkermes, INC. | $600.94 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $556.29 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Abbvie INC. | $535.19 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $477.86 | 2021-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $426.50 | 2021-2024 | Qelbree, Qelbree |
| Corium, LLC | $354.66 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $286.36 | 2020-2024 | Trintellix |
| Axsome Therapeutics, INC. | $273.87 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $188.82 | 2024-2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $81.15 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $61.82 | 2024-2025 | Xelstrym, Secuado |
| Sunovion Pharmaceuticals INC. | $56.26 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $55.60 | 2022-2023 | Belsomra |
| Ironshore Pharmaceuticals INC. | $47.33 | 2022-2023 | Jornay Pm |
| Acadia Pharmaceuticals INC | $43.78 | 2024 | Nuplazid |
| Neuronetics, INC. | $41.50 | 2021-2025 | Neurostar Tms Therapy System |
| Almatica Pharma LLC | $39.38 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $34.56 | 2025 | Jornay Pm |
| Eisai INC. | $31.81 | 2020-2022 | |
| Tris Pharma INC | $23.17 | 2023 | Dyanavel Xr |
| Allergan, INC. | $15.97 | 2020 | |
| Bausch Health US, LLC | $14.67 | 2022 | |
| Indivior INC. | $13.77 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.66 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Chau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.